Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Paclitaxel (260mg) Injection
Therapeutic Category
Oncology, Anticancer
Dosage Form
Injection
Packaging Type
Vial
Packaging
260mg
Price
₹1/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
Packlin 260 Injection is a large-volume, intravenous chemotherapy solution containing Paclitaxel 260 mg, a cornerstone drug in the Taxane class. This large presentation is specifically designed for institutional purchasing, high-dose protocols, and maximizing inventory efficiency in major oncology centers and hospitals.
Mechanism and Impact:Paclitaxel is a cytotoxic agent that acts by stabilizing microtubules, preventing their breakdown and essential restructuring required for cell division. This mechanism leads to the arrest of mitosis and the eventual death of rapidly dividing cancer cells, making it highly effective against aggressive solid tumors.
Key Therapeutic Uses:
Breast Cancer: Used in adjuvant, neoadjuvant, and metastatic settings.
Ovarian Cancer: Standard treatment for advanced ovarian carcinoma.
Non-Small Cell Lung Cancer (NSCLC): Used in combination regimens.
Institutional Efficiency: The large 260 mg vial size is critical for optimizing procurement and dispensing in high-volume settings.
We offer an exclusive PCD Pharma Franchise opportunity for Packlin 260 Injection, enabling partners to meet the strong institutional demand for high-volume, reliable oncology injectables at a competitive commercial value.
Hair loss (alopecia) Nausea, vomiting, diarrhea Low blood counts (anemia, leukopenia) Peripheral neuropathy (tingling or numbness) Joint/muscle pain
Metastatic breast cancer Advanced ovarian carcinoma Non-small cell lung cancer (NSCLC) AIDS-related Kaposi’s sarcoma Often used as first-line or second-line therapy, either alone or in combination with other chemotherapeutic agents like cisplatin.
Administered intravenously by trained professionals in a clinical setting. Premedication with corticosteroids, antihistamines, and H2 antagonists is essential to minimize hypersensitivity reactions. Requires close monitoring of blood counts, liver function, and cardiac status.
Store below 25°C, protected from light. Do not freeze. Shake well before use. Keep out of reach of children.
Composition : Abiraterone 250 Mg Tablet
Composition : Acebrophylline (100mg) + Acetylcysteine (600mg)
Composition : Acetylcysteine (600mg) effervescent
Composition : Paclitaxel (100mg) Injection
Composition : Aceclofenac (200mg) + Rabeprazole (20mg) Capsule
Composition : Lactic acid bacillus (100Million spores) + Saccharomyces boulardii (250mg) + Zinc (10mg)
Composition : Glimepiride (1mg) + Metformin (500mg) SR Bilayered Smart Tablet
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.
Paclitaxel IP 6mg/mL Injection has strong demand in the oncology, hospital, and specialty healthcare segment, making it a valuable product for medical distributors, wholesalers, and pharma franchise partners focusing on oncology and institutional pharmaceutical portfolios.
Medical distributors and agencies can benefit from consistent demand for chemotherapy medicines under specialist medical supervision. Paclitaxel IP 6mg/mL is a taxane-based antineoplastic (chemotherapy) agent that inhibits cancer cell division by stabilizing microtubules The formulation contains Polyoxyl 35 Castor Oil IP and Dehydrated Alcohol IP as solubilizing agents to facilitate intravenous administration Commonly prescribed for the treatment of breast cancer, ovarian cancer, non-small cell lung cancer (NSCLC), AIDS-related Kaposi's sarcoma, and other solid tumors, either alone or in combination with other anticancer medicines, as advised by oncologists Helps slow or stop the growth of cancer cells and forms an integral part of several standard chemotherapy protocols Injectable formulation is administered intravenously by trained healthcare professionals in hospitals or oncology infusion centers Requires strict medical supervision with appropriate premedication and regular monitoring for hypersensitivity reactions, blood counts, liver function, and overall treatment response Frequently utilized in oncology departments, cancer hospitals, day-care chemotherapy centers, and tertiary care institutions Widely prescribed by medical oncologists and oncology specialists This strengthens a comprehensive oncology and hospital specialty portfolio.
Yes, Cafoli LifeCare Pvt Ltd offers PCD pharma franchise opportunities for Paclitaxel IP 6mg/mL Injection with promotional support, monopoly rights, attractive packaging, competitive pricing, and dependable institutional supply for distributors and wholesalers.
Wholesalers and medical agencies benefit from consistent institutional demand, high-value oncology procurement, reliable supply chain support, specialty healthcare market opportunities, and attractive margins in the oncology injectable segment.
Interested distributors, stockists, wholesalers, and institutional suppliers can partner with Cafoli LifeCare Pvt Ltd to access lucrative PCD pharma franchise opportunities across India. With exclusive monopoly rights, extensive promotional support, high-quality oncology products, attractive business margins, and dependable logistics support, Cafoli LifeCare Pvt Ltd helps franchise partners build a successful and profitable pharmaceutical business.